ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease

•This special article provides updated treatment recommendations for nasopharyngeal carcinoma.•In high-risk locoregionally advanced NPC, adding metronomic or standard dose adjuvant capecitabine to CRT improves PFS.•Immunotherapy added to platinum and gemcitabine improves PFS as first-line metastatic treatment in endemic NPC areas.